[Novel immunomodulatory therapies in myasthenia gravis]

Eglé Sukockiené,Marie Théaudin,Valentin Loser,Katia Staedler,Patrice H Lalive,Agustina M Lascano
DOI: https://doi.org/10.53738/REVMED.2024.20.871.848
2024-04-24
Abstract:Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating weakness of skeletal muscles. Despite current treatments, a significant percentage of patients remain symptomatic. This review explores new immunosuppressive therapies and ongoing clinical trials in MG, including depletion of B lymphocytes with agents such as rituximab and inebilizumab, as well as the use of eculizumab, efgartigimod, satralizumab, tocilizumab, and CAR-T (Chimeric Antigen Receptor-T) cell therapy. These advancements aim to improve disease control and patients' quality of life.
What problem does this paper attempt to address?